Verve Therapeutics, Inc. - Common Stock (VERV)
11.23
+4.96 (79.11%)
NASDAQ · Last Trade: Jun 17th, 1:59 PM EDT
Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.
Via Chartmill · June 17, 2025
Via Benzinga · June 17, 2025
The market is filled with gapping stocks in Tuesday's session. Let's discover which stocks are showing gap-ups and gap-downs.
Via Chartmill · June 17, 2025
Lilly will acquire all outstanding shares of Verve for $10.50 per share in cash payable at closing, in addition to a contingent value right (CVR) per share that entitles holders to $3 per share, subject to the completion of certain milestones.
Via Stocktwits · June 17, 2025
The companies were already collaborating on a handful of cardiovascular-focused gene-editing treatments.
Via Investor's Business Daily · June 17, 2025
Before the opening bell on Tuesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.
Via Chartmill · June 17, 2025
Via Benzinga · June 17, 2025
Eli Lilly is acquiring Verve Therapeutics to strengthen its cardiovascular pipeline with a gene-editing drug targeting PCSK9-linked conditions.
Via Benzinga · June 17, 2025
Via Benzinga · June 17, 2025
The deal would double Verve’s market value and expand Lilly’s pipeline of early-stage therapies.
Via Stocktwits · June 16, 2025
CRISPR reports data showing dose-dependent lipid reduction and strong safety, with plans to present full results in late 2025.
Via Benzinga · May 7, 2025
Via The Motley Fool · April 29, 2025
Via Benzinga · April 21, 2025
Let's have a look at the stocks with an unusual volume in today's session.
Via Chartmill · April 15, 2025
Via Benzinga · April 15, 2025
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Tuesday.
Via Chartmill · April 15, 2025
Via Benzinga · April 15, 2025
Via Benzinga · April 14, 2025
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Monday.
Via Chartmill · April 14, 2025
Verve shares Phase 1b results of VERVE-102, showing dose-dependent LDL-C reductions and strong safety in patients with HeFH or premature CAD.
Via Benzinga · April 14, 2025